Seth Klarman's stock portfolio includes Jazz Pharmaceuticals Plc, showing strong growth potential and financial performance. With key products like Xywav and Epidiolex driving revenue, Jazz Pharmaceuticals is poised for further growth with new drug developments in its pipeline.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing